Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Wajeeh Khan

Exact Sciences Stock Pops on $21 Billion Deal. Is It Too Late to Buy EXAS Here?

Exact Sciences (EXAS) shares soared roughly 20% on Thursday morning after Abbott (ABT) said it’s buying the molecular diagnostics firm in a deal that values it at $21 billion. 

Abbott is paying $105 for each EXAS shares, a significant premium on their previous close, as this transaction will grow its presence in the fast-growing cancer diagnostics market. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.